Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601 Other Scholarly Work

cited authors

  • De Groot, JF; Wen, PY; Lamborn, K; Chang, S; Cloughesy, TF; Chen, AP; DeAngelis, LM; Mehta, MP; Gilbert, MR; Yung, WK; Prados, MD

sustainable development goals

authors

publication date

  • May 20, 2008

published in

keywords

  • Life Sciences & Biomedicine
  • Oncology
  • Science & Technology

WoS ID

  • 000208457400518

Digital Object Identifier (DOI)

volume

  • 26

issue

  • 15